Study finds over-treatment for prostate cancer patients with life expectancies of fewer than 10 years

December 11, 2014 by Kim Irwin, University of California, Los Angeles

National guidelines recommend that men with low- and intermediate-risk prostate cancer who have life expectancies of fewer than 10 years should not be treated with radiation or surgery, since they are unlikely to live long enough to benefit from treatment. Yet a new study by UCLA researchers found that more than half of such men are receiving these aggressive treatments putting them at risk for potentially debilitating side effects.

In the first study to rigorously address trends by life expectancy in a large, nationally representative sample, UCLA researchers found that more than half of prostate cancer patients 66 years and older have life expectancies of fewer than10 years, but half of those still were over-treated for their prostate cancer with surgery, radiation or brachytherapy—the implantation of radioactive seeds in the prostate.

Randomized controlled studies have suggested that significant differences in survival between watchful waiting—monitoring the cancer closely but not treating it—and aggressive therapies don't develop until 10 years after treatment. Thus it makes sense not to treat men expected to die of something else within 10 years. But the UCLA researchers found that men were being treated aggressively anyway, with little regard for their quality of life, said study first author Dr. Timothy Daskivich, a UCLA Robert Wood Johnson fellow.

"Life expectancy is poorly integrated into treatment decision-making for prostate cancer, yet it is one of the primary determinants of whether a patient will benefit from treatment with surgery or radiation," Daskivich said. "Because these treatments have side effects such as erectile dysfunction, urinary incontinence and bowel problems, it's critical for men with limited life expectancies to avoid unnecessary treatment for low- and intermediate-risk prostate cancer."

Prostate cancer affects one in six men and is the second-most frequently diagnosed cancer in males after skin cancer. An estimated 233,000 new cases of prostate cancer will occur in the United States in 2014. Of those, nearly 30,000 men will die. For reasons that remain unclear, incidence rates are about 60 percent higher in African Americans.

The study is a cover article in the Dec. 1 issue of the peer-reviewed journal Cancer.

Researchers sampled 96,032 men aged 66 and older with early-stage prostate cancer diagnosed from 1991 to 2007 using the Surveillance, Epidemiology and End Results (SEER) Medicare database. They calculated life expectancy using the patient's age and other medical conditions at diagnosis and then determined treatment patterns in those men whose life expectancies were fewer than 10 years.

Men with life expectancies of fewer than 10 years based on their health statuses were grouped into four age ranges and the research team found that:

  • Men aged 66 to 69 were treated aggressively with radiation, surgery or radioactive seed implants 68 percent of the time.
  • Men 70 to 74 were treated aggressively 69 percent of the time.
  • Men 75 to 79 received 57 percent of the time.
  • Men 80 and older were treated aggressively 24 percent of the time.

"Describing treatment trends by both age and health status is key, because younger, sicker men may have life expectancies of less than 10 years, while older, healthier men may have life expectancies longer than 10 years," Daskivich said. "This information will help men with newly diagnosed low- and intermediate-risk prostate cancer understand their likelihood of living long enough to benefit from aggressive treatment. It will also raise awareness among clinicians that a large number of men older than 65 are at risk for having life expectancies of less than 10 years. Hopefully, these results will promote integration of this information into treatment decision-making discussions."

Daskivich and his team will attempt to determine how these findings will affect treatment decision-making for men with prostate cancer, and whether the trend to over-treat men 66 and older with low- and intermediate-risk will continue.

"Because of their low likelihood of 10-year survival, these men are unlikely to live long enough to substantially benefit from aggressive treatment, but they still incur its associated side effects and financial burden," the study states. "We hope that this information will promote greater awareness of the role of in decision-making for with low- and intermediate-risk disease."

Explore further: Older, sicker men with early-stage prostate cancer do not benefit from aggressive treatment

More information: "Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer." Cancer, 120: 3642–3650. doi: 10.1002/cncr.28926

Related Stories

Older, sicker men with early-stage prostate cancer do not benefit from aggressive treatment

May 13, 2014
Treating older men with early-stage prostate cancer who also have other serious underlying health problems with aggressive therapies such as surgery or radiation therapy does not help them live longer and, in fact, can be ...

Common prostate cancer treatment associated with decreased survival in older men

December 3, 2014
A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital.

Older prostate cancer patients should think twice before undergoing treatment

May 20, 2013
Older prostate cancer patients with other underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by researchers in the UCLA ...

Popular prostate cancer therapy may be harmful

October 23, 2014
A widely used treatment for prostate cancer may cause more harm than good for some patients, according to Dr. Oliver Sartor, medical director of the Tulane Cancer Center.

Depressed men with prostate cancer are diagnosed later stage, get less effective therapies

July 10, 2014
Depressed men with localized prostate cancer were more likely to be diagnosed with more aggressive prostate cancer, received less effective treatments and survived for shorter times than prostate cancer patients who were ...

Benefit of aggressive prostate CA Tx weakens as comorbidity rises

May 21, 2014
(HealthDay)—For men with early-stage prostate cancer, the cancer-specific survival benefit associated with aggressive prostate cancer treatment is reduced with increasing comorbidity, according to a study published online ...

Recommended for you

Solving the mystery of NPM1 in acute myeloid leukemia

November 13, 2018
Although it has long been recognized that mutations of gene NPM1 play an important role in acute myeloid leukemia, no one has determined how the normal and the mutated forms of the protein NPM1 function.

Cognitive decline—radiation—brain tumor prevented by temporarily shutting down immune response

November 13, 2018
Treating brain tumors comes at a steep cost, especially for children. More than half of patients who endure radiation therapy for these tumors experience irreversible cognitive decline, a side-effect that has particularly ...

Study finds promising therapeutic target for aggressive type of breast cancer

November 13, 2018
A new Nature Communications study led by University of Kentucky Markey Cancer Center researchers suggests that an enzyme known as Prolyl 4-hydroxylase subunit alpha-1 (P4HA1) is a potential therapeutic target for triple negative ...

Scientists shine new light on link between obesity and cancer

November 12, 2018
Scientists have made a major discovery that shines a new, explanatory light on the link between obesity and cancer. Their research confirms why the body's immune surveillance systems—led by cancer-fighting Natural Killer ...

Obesity both feeds tumors and helps immunotherapy kill cancer

November 12, 2018
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors.

Two-pronged device enables maverick immune cells to identify and kill cancers

November 12, 2018
Immune cells called Gamma Delta T cells can act independently to identify and kill cancer cells, defying the conventional view of the immune system, reveals new research from the Francis Crick Institute and King's College ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.